Кровосбережение в детской кардиохирургии
Диссертация
Особое внимание уделяется кровосбережению в педиатрической и, особенно, неонатальной кардиохирургии, что связано не только с высокой чувствительностью маленьких пациентов к кровопотере, но и массой факторов, способных её усугубить в ходе и после операции. Это и функциональная незрелость системы гемостаза, преимущественно характеризующаяся низкой концентрацией факторов свёртывания, и различные… Читать ещё >
Содержание
- Принятые в диссертации сокращения
- Глава I. Причины повышенной кровоточивости в детской кардиохирургии
- 1. 1. Хирургические возможности предупреждения и лечения кровотечений при операциях с искусственным кровообращением
- 1. 2. Система гемостаза как непременное условие возможности существования хирургии как медицинской специальности
- 1. 2. 1. Роль эндотелия в гемостазе
- 1. 2. 2. Тромбоцитарный гемостаз
- 1. 2. 3. Коагуляционный гемостаз
- 1. 2. 4. Современная модель свертывания крови
- 1. 2. 5. Фибринолиз
- 1. 2. 6. Естественные антикоагулянты
- 1. 3. Система гемостаза у детей
- 1. 4. Влияние искусственного кровообращения на систему свёртывания крови
- 1. 4. 1. Роль сериновых протеаз и их ингибиторов в патологии повреждений, обусловленных искусственным кровообращением
- 2. 1. Методы исследования
- 2. 1. 1. Инструментальные методы диагностики врождённого порока сердца
- 2. 1. 2. Лабораторные методы исследования
- 2. 2. Характеристика клинического материала
- 2. 2. 1. Исходное состояние пациентов в целом
- 2. 2. 2. Объем и условия выполнения оперативных вмешательств в целом
- 2. 2. 3. Характеристика подгруппы пациентов с расширенным изучением системы гемостаза («малой когорты»)
- 2. 3. Дизайн исследования, конечные точки и принципы формирования групп
- 2. 4. Статистические методы обработки результатов
- 3. 1. Влияние демографических, педиатрических и кардиологических факторов на развитие периоперационных геморрагических осложнений
- 3. 1. 1. Интраоперационные кровотечения и кровопотеря
- 3. 1. 2. Послеоперационные геморрагические осложнения
- 3. 1. 2. 1. Послеоперационные кровотечения
- 3. 1. 2. 2. Послеоперационные кровопотеря и гемотрансфузии
- 3. 2. 1. Влияние хирургических факторов на развитие интраоперационных геморрагических осложнений
- 3. 2. 2. Влияние хирургических факторов на развитие послеоперационных геморрагических осложнений
- 3. 2. 3. Факторы, определяющие потребность в дополнительном хирургическом гемостазе
- 3. 2. 4. Влияние хирургических факторов на потребность в переливании компонентов крови
- 3. 3. 1. Взаимные влияния параметров искусственного кровообращения друг на друга (ограничения анализа)
- 3. 3. 2. Операционный этап: кровотечения и кровопотеря, время гемостаза и объём гемотрансфузий
- 3. 3. 3. Послеоперационный этап: кровотечения и кровопотеря, время гемостаза и объём гемотрансфузий
- 3. 3. 4. Влияние условий искусственного кровообращения на параметры системы гемостаза
- 3. 4. 1. Коагуляционные функции эндотелия
- 3. 4. 2. Тромбоцитарный и коагуляционный гемостаз
- 3. 4. 2. 1. Взаимосвязь между лабораторными параметрами системы свёртывания крови
- 3. 4. 2. 2. Влияние циркуляторной гипоксии на показатели свёртывания крови
- 3. 4. 2. 3. Операционный этап: кровотечения и кровопотеря, время гемостаза и объём гемотрансфузий
- 3. 4. 2. 4. Послеоперационный этап: кровотечения и кровопотеря, время гемостаза и объём гемотрансфузий
- 3. 4. 3. Система фибринолиза
- 3. 4. 3. 1. Послеоперационные геморрагические осложнения
- 3. 4. 3. 2. Влияние исходного состояния пациентов на послеоперационную активность фибринолиза
- 3. 4. 3. 3. Влияние искусственного кровообращения на фибринолиз
- 3. 4. 3. 4. Динамика активности фибринолиза в раннем послеоперационном периоде
- 3. 4. 3. 5. Топический фибринолиз
- 3. 5. 1. Влияние апротинина на периоперационные кровотечения
- 3. 5. 1. 1. Превентивное применение апротинина
- 3. 5. 1. 2. Лечебное применение апротинина
- 3. 5. 2. Органные эффекты и безопасность применения апротинина
- 4. 1. Факторы риска развития периоперационных геморрагических осложнений
- 4. 1. 1. Демографические, педиатрические и кардиологические предикторы периоперационных геморрагических осложнений
- 4. 1. 2. Хирургические предикторы периоперационных геморрагических осложнений
- 4. 1. 3. ИК-ассоциированные предикторы периоперационных геморрагических осложнений
- 4. 2. Взаимосвязь состояния системы свёртывания крови с риском развития периоперационных геморрагических осложнений
- 4. 2. 1. Роль эндотелиальной дисфункции в развитии коагуляционных нарушений после операций с искусственным кровообращением
- 4. 2. 2. Влияние состояния тромбоцитарного и коагуляционного гемостаза на развитие периоперационных кровотечений
- 4. 2. 3. Влияние состояния системы фибринолиза на развитие периоперационных кровотечений
- 4. 3. Способы профилактики и терапии периоперационных кровотечений
- 4. 3. 1. Хирургические пути уменьшения кровопотери
- 4. 3. 1. 1. Общие вопросы обеспечения хирургического гемостаза
- 4. 3. 1. 2. Биомеханика сосудистой стенки как компонент обеспечения гемостаза
- 4. 3. 1. 3. Место топических средств в обеспечении гемостаза
- 4. 3. 2. Предупреждение кровопотери за счет оптимизации условий проведения искусственного кровообращения
- 4. 3. 2. 1. Модификация контуров аппарата искусственного кровообращения
- 4. 3. 2. 2. Ультрафильтрация
- 4. 3. 2. 3. Клеточные сепараторы
- 4. 3. 2. 4. Использование свежей цельной крови в-первичном объеме заполнения аппарат ИК
- 4. 3. 3. Фармакологические пути уменьшения кровопотери
- 4. 3. 3. 1. Препараты, влияющие на скорость коагуляционного гемостаза
- 4. 3. 3. 2. Препараты, влияющие на этап стабилизации тромба
- 4. 3. 3. 3. Антифибринолитики
- 4. 3. 1. Хирургические пути уменьшения кровопотери
- 4. 4. 1. Способ выбора мероприятий, направленных на предупреждение периоперационной кровопотери
- 4. 4. 2. Дифференцированная терапия послеоперационных кровотечений
Список литературы
- Абакумов М.М. Оксид азота и свёртывающая система крови в клинике. / Абакумов М. М., Голиков П. П. // Вестник РАМН 2005. — № 10. — С. 53−56.
- Аверина Т.Б. Особенности перфузии у детей с массой тела до 5 кг: дис.. канд. мед. наук / Аверина Т. Б. М., 2010. — 208 с.
- Амосов Н.М. Операции на сердце с искусственным кровообращением. / Амосов Н. М., Лиссов И. Л., Сидаренко Л. Н. Киев: Госмедиздат УССР, 1962. — 246 с.
- Арсентьев В.Г. Клинические и патогенетические аспекты нарушений в системе гемостаза при дисплазиях соединительной ткани у детей. / Арсентьев В. Г., Пшеничная К. И., Суворова A.B. и др. // Педиатрия. 2009. — № 4. — С. 134−140.
- Балуда В.П. Физиология системы гемостаза. / Балуда В. П., Балуда М. В., Деянов И. И., Тлепшуков И. К. М., 1995. — 243 с.
- Баркаган З.С. Геморрагические заболевания и синдромы. / Баркаган З. С. М.: Медицина, 1988. — 528 с.
- Баркаган Л.З. Нарушение гемостаза у детей. / Баркаган Л. З. М.: Медицина, 1993. — 176 с.
- Бокерия Г. Д. Причины и результаты повторных операций после ранее выполненной радикальной коррекции врождённых пороков сердца у детей раннего возраста: дисс.. канд. мед. наук. / Бокерия Г. Д. -М., 2007. 150 с.
- Бокерия Л.А. Клиническое применение нового биологического клея «Биоклей-ЛАБ» при операциях на сердце в условиях искусственного кровообращения. / Бокерия Л. А., Муратов P.M., Межнева В. В. и соавт. // Хирургия. 2005. — № 1. — Стр. 18−20.
- Бокерия Л.А. Результаты применения рекомбинантного активированного фактора свёртывания VII в кардиохирургии детского возраста. / Бокерия Л. А., Диасамидзе К. Э., Ким А. И. и др. // Детские болезни сердца и сосудов. 2006. — № 1. — Стр. 59−62.
- Бокерия Jl.А. Недостаточность фактора XIII после операций с искусственным кровообращением у детей. / Бокерия Л. А., Самсонова H.H., Юрлов И. А. и др. // Мат-лы XII ежегодной сессии НЦССХ им. А. Н. Бакулева РАМН. Москва, май 2008. — С. 143
- Бокерия Л.А. Клиника повреждений центральной нервной системы в кардиохирургии. / Бокерия Л. А., Ваничкин A.B., Лобачёва Г. В. // Бюллетень НЦССХ им. А. Н. Бакулева РАМН 2008 — № 6 — с. 5−14.
- Бокерия Л. А. Диагностика, профилактика и контроль лечения нарушений свёртывающей системы крови в кардиохирургии. / Бокерия Л. А., Самсонова H.H., Климович Л. Г. // Грудная и серд.-сосуд. хир. 2009. — № 5. -Стр. 45−52.
- Болотина Ё.Д. Становление адгезивно-агрегационной функции тромбоцитов при перинатальной гипоксии новорожденных. / Болотина Е. Д., Шабалов Н. П., Карам М. // Педиатрия. 1985. — № 12. — С. 23−26.
- Бураковский В.И. Осложнения при операциях на открытом сердце. (Основы реаниматологии в кардиохирургии). / Бураковский В. И. Рапопорт Я.Л., Гелыптейн Г. И. и др. М.: «Медицина», 1972. — 304 с.
- Дементьева И.И. О механизме действия рекомбинантного активированного фактора Vila при массивных кровотечениях негемофильной природы у кардиохирургических больных. / Дементьева И. И., Гладышева
- B.Г., Чарная М. А., Морозов Ю. А. // Вестник РАМН. 2006. — № 12. — Стр. 2125.
- Дементьева И.И. Система гемостаза при операциях на сердце и магистральных сосудах. Нарушения, профилактика, коррекция. / Дементьева И. И., Чарная М. А., Морозов Ю. А. М.: ГЭОТАР-Медиа, 2009. — 432 стр.
- Дериан С.К. Регуляция тромбином клеточных функций через рецепторы, расщепляемые протеиназами: применение для терапии. / Дериан
- C.К., Демиано Б. П., Д’Андре М. Р., Андраде-Гордон П. // Биохимия. 2002. -Т. 67. — Стр. 66−77.
- Долгов B.B. Лабораторная диагностика нарушений гемостаза. / Долгов В. В., Свирин П. В. М.-Тверь: ООО «Издательство «Триада», 2005. — 227 с.
- Карам М. Становление адгезивно-агрегационной функции тромбоцитов в раннем неонатальном периоде: автореф. дис.. канд. мед. наук. / Карам М. -Д., 1984.-26 с.
- Киричук В.Ф. Функции эндотелия сосудистой стенки. / Киричук В. Ф., Ребров А. П., Россошанская С. И. // Тромбоз, гемостаз, реология. 2005. -№ 2(22). — Стр. 23−29.
- Климович Л.Г. Механизмы нарушений гемостаза у больных с синдромом лёгочной гипертензии. / Климович Л. Г., Белкина М. В., Трошнева А. Ю. и др. // Детские болезни сердца и сосудов. 2006. — № 4. — С. 11−15.
- Козар Е.Ф. Состояние гемостаза у больных врождёнными пороками сердца до и после хирургической коррекции. / Козар Е. Ф., Плющ М. Г., Самсонова H.H., Климович Л. Г. // Тромбоз, гемостаз и реология. 2001. -№ 2(6). — Стр. 27−29.
- Морозов Ю.А. Система фибринолиза после операций на сердце в условиях искусственного кровообращения: дисс.. канд. мед. наук. / Морозов Ю. А. М., 2006. — 127 стр.
- Неонатология. Национальные рекомендации. / Под ред. Володина H.H. М.: ГЭОТАР-Медиа, 2008. — 749 с.
- Панченко Е.П. Тромбозы в кардиологии. Механизмы развития и возможности терапии. // Панченко Е. П., Добровольский А. Б. М.: Спорт и культура, 1999. — 464 стр.
- Подзолков В.П. Реоперации после радикальной коррекции тетрады Фалло. / Подзолков В. П., Чебан В. Н., Гаджиев A.A. и соавт. // Анналы хирургии. 1999. — № 6. — с. 41−45.
- Пучков К.В. Новые синтетические шовные материалы. / Пучков К. В., Селиверстов Д. В., Полит Г. Г., Гаусман Б. Я. Рязань, 1994. — 43 с.
- Самсонова H.H. Характеристика системы гемостаза у кардиохирургических пациентов первого года жизни с врождёнными пороками сердца. / Самсонова H.H., Козар Е. Ф., Плющ М. Г. с соавт. // Детские болезни сердца и сосудов. 2005. — № 4. — Стр. 54−58.
- Свободов A.A. Способ безопасной рестернотомии. / Свободов A.A., Зеленикин М. А. // Грудная и сердечно-сосудистая хирургия. 2008 г. — № 1. -С. 66−67.
- Соловьев Г. М. Кровопотеря и регуляция кровообращения в хирургии. / Соловьев Г. М., Радзивил Г. Г. М.: Медицина, 1973. — 335 с.
- Стуров В.Г. Структурно-функциональные нарушения конечного этапа свёртывания крови у пациентов с диспластическими синдромами. / Стуров В. Г., Чупрова A.B., Антонов А. Р. и др. // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. 2007. — № 2 — С. 28−37.
- Флетчер Р. Клиническая эпидемиология. Основы доказательной медицины. / Флетчер Р., Флетчер С., Вагнер Э. Пер. с англ. М.: Медиа Сфера, 1998. — 352 с.
- Чебан В.Н. Повторные операции после коррекции врождённых пороков сердца: дисс.. докт. мед. наук. / Чебан В. Н. М., 2003 — с. 303.
- Чупрова A.B. Состояние фибринолитической системы крови у новорожденных. //Педиатрия. 1987.- № 9. — Стр. 13−16.
- Чупрова A.B. Состояние моноцитарного механизма активации свертывания крови у детей первых месяцев жизни. / Чупрова A.B., Пименова Н. В., Пикалов И. В., Белоусова Т. В. // Педиатрия. 1996. — № 5. — Стр.9−12.
- Чупрова A.B. Система неонатального гемостаза в норме и при патологии. // Бюллетень СО РАМН. 2005. — № 4. — Стр. 13−19.
- Шабалов Н.П. Особенности тромбоцитарного звена гемостаза у новорожденных детей и некоторые механизмы его нарушений. / Н. П. Шабалов //Гематология и трансфузиология. 1991. — № 5. — С. 10−14.
- Шаталов К. В. Хирургическая коррекция врожденных пороков сердца у детей с гемофилией А. / Шаталов К. В., Самсонова Н. Н., Свирин П. В. и др. // Бюллетень НЦССХ им. А. Н. Бакулева РАМН. 2008. — Т. 9, № 6. — С. 14.
- Шипулин В.М. Ультрафильтрация крови в детской кардиохирургии. / Шипулин В. М., Мерунко A.A. Томск: STT, 2002. — 136 с.
- Шитикова A.C. Тромбоцитарный гемостаз. / Шитикова A.C. СПб.: Издательство СПбГМУ, 2000. — 227 с.
- Abercrombie D.M. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin. / Abercrombie292
- D.M., Buchinski B., Salavato K.A. et al. // Thromb. Haemosta. 1990. — Vol. 64. -P. 426−432.
- Adelman B. Plasmin effect on platelet glycoprotein lb-von Willebrand factor interactions. / Adelman B., Michelson A.D., Loscalzo J. et al. // Blood. -1985.-Vol. 65.-P. 32- 40.
- Agarwal H. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. / Agarwal H., Bennett J., Churchwell K. et al. // Ann. Thorac. Surg. 2007. — Vol. 84. — P. 161−169.
- Alston T.A. Aprotinin. // Int. Anesthesiol. Clin. 2004. — Vol. 42. — P. 8191.
- Andrew M. Development of the human coagulation system in the full-term infant. / Andrew M., Paes B., Milner R. et al. // Blood. 1987. — Vol. 70. — P 165 172.
- Andrew M. Development of the human coagulation system in the healthy premature infant. / Andrew M., Paes B., Milner R. et al. // Blood. 1988. — Vol. 72. — P. 1651−1657.
- Andrew M. Fibrinogen has a rapid turnover in the healthy newborn lamb. / Andrew M., Mitchell U., Berry U.R. et al. // Pediatr. Res. 1988. — Vol. 23. — P. 249−252.
- Andrew M. Development of the hemostatic system in the neonate and young infant. / Andrew M., Paes B., Johnston M. // Am. J. Pediatr. Hematol. Oncol. -1990. Vol. 12. — P. 95−104.
- Andrew M. Evaluation of an automated bleeding time device in the newborn. / Andrew M., Paes B., Bowker J., et al. // Am. J. Hematol. 1990. — Vol. 35.-P. 275−277.
- Andrew M. Maturation of the hemostatic system during childhood. / Andrew M., Vegh P., Johnston M. et al. // Blood. 1992. — Vol. 80. — P. 1998−2005.
- Angiolillo D.J. Basic principles of platelet biology and clinical implications / Angiolillo D.J., Ueno M., Goto Sh. // Circ. J. 2010. — Vol. 74. — P. 597−607.
- Anttila V. Aprotinin improves cerebral protection: evidence from a survival porcine model. / Anttila V., Hagino I., Iwata Y. et al. // J. Thorac. Cardiovasc. Surg. 2006. — Vol. 132. — P. 948−953.
- Arnold D.M. Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. / Arnold D.M., Fergusson D.A., Chan A.K. et al. // Anesth. Analg. 2006. — Vol. 102. — P. 731−737.
- Asimakopoulos G. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. / Asimakopoulos G., Thompson R., Nourshargh S. et al. // J. Thorac. Cardiovasc. Surg. 2000. — Vol. 120. — P. 361 369.
- Autret-Leca E. Vitamin K in neonates: how to administer, when and to whom. / Autret-Leca E., Jonville-Bera A.P.// Paediatr Drugs. 2001. — Vol. 3. — P. 1−8.
- Bachmann F. Fibrinolysis. // B kh.: Thrombosis and Haemostasis. Eds. Verstraete M., Vermylen J., Lijnen H.R., Arnout J. — Leuven. — 1987. — P. 227−265.
- Backer C.L. Aprotinin is safe in pediatric patients undergoing cardiac surgery. / Backer C.L., Kelle A.M., Stewart R.D. et al. // J. Thorac. Cardiovasc. Surg. 2007. — Vol. 134. — P. 1421−1426.
- Bando K. Effect of modified ultrafiltration in high-risk patients undergoing operations for congenital heart disease. / Bando K., Turrentine M.W., Vijay P. et al. // Ann. Thorac. Surg. 1998. — Vol. 66. — P. 821−828.
- Baran D. Aprotinin uptake in the proximal tubules in the rat kidney. I. Length of proximal tubular uptake segment. / Baran D., Tenstad O., Aukland K. // J. Struct. Biol. 2003. — Vol. 142. — P. 402−408.
- Baran D. Aprotinin uptake in the proximal tubules in the rat kidney. II. Uptake site relative to glomerulus. / Baran D., Tenstad O., Aukland K. // J. Struct. Biol.-2003.-Vol. 142.-P. 409−415.
- Barnard J. A review of topical hemostatic agents for use in cardiac surgery. / Barnard J., Millner R. // Ann. Thorac. Surg. 2009. — Vol. 88. — P. 1377−1383.
- Bartley T. Identification and cloning of a megakaryocyte growth factor that is a ligand for the cytokine receptor. / Bartley T., Bogenberger J., Hunt P. et al. // Mpl. Cell. 1994. — Vol. 7. — P. 1117−1124.
- Bates J.N. EDRF: nytrosylated compound or authentic nitric oxide. / Bates J.N., Narrison D.G., Myers P.R. et al. // Basic. Res. Cardiol. 1991. -Vol.86(Suppl.2). — P. 17−26.
- Baufreton C. Heparin coating with aprotinin reduces blood activation during coronary artery operations. / Baufreton C., Jansen P.G., LeBesnerais P. // Ann. Thorac. Surg. 1997. — Vol. 63. — P.50−56.
- Beath S.M. Plasma aprotinin concentrations during cardiac surgery: full-versus half-dose regimens. / Beath S.M., Nuttall G.A., Fass D.N. et al. // Anesth. Analg. 2000 — Vol. 91. — P. 257−264.
- Bennett-Guerrero E. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. / Bennett-Guerrero E., Sorohan J.G., Howell S.T. et al. // Anesth. Analg. 1996. — Vol. 83. -P. 1189−1192.
- Beuchelt H. Trasylol, ein Proteinasen-Inhibitor in Experiment und klinischer Anwendung. // Med. Chem. 1963. — Vol. 7. — P.763−768.
- Bick R.L. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorpopal circuits. // Semin. Thromb. Hemost. 1985. -Vol. 11.-P. 249−280.
- Bikhazi G.B., Cook D.R. Perioperative fluid therapy and blood replacement. // B kh.: Motoyama E.K., Davis P.J., eds. Smith’s anesthesia for infants and children. 5th ed. St. Louis: CV Mosby, 1990. — P. 338−343.
- Billiar T.R. Nitric oxide: novel biology with clinical relevance. / Billiar T.R. //Ann. Surg. 1995. — Vol. 221. — P. 339−349.
- Bogers A.J. Massive bleeding at resternotomy despite a polytetrafluoroethylene surgical membrane. / Bogers A J. // J. Thorac. Cardiovasc. Surg. 1995. — Vol. 110. — P. 274−275.
- Boisciair M.D. Mechanism of thrombin generation during surgery and cardiopulmonary bypass. / Boisciair M.D., Lane D.A., Philippou H. et al. // Blood. 1993. — Vol. 82. — P. 3350−3357.
- Boldt J. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood. / Boldt J., Knothe C., Zickmann B. et al. // Ann. Thorac. Surg. 1993. — Vol. 55. — P. 1460−1466.
- Boldt J. Comparison of two aprotinin dosage regiments in pediatric patients having cardiac operations. / Boldt J., Knothe C., Zickmann B. et al. // J. Thorac. Cardiovasc.Surg. 1993. — Vol. 105. — P. 705−711.
- Boldt J. Influence of aprotinin on the thrombomodulin/protein c system in pediatric cardiac operations. / Boldt J., Zickmann B., Schindler E. et al. // J. Thorac. Cardiovasc.Surg. 1994. -Vol. 107.-P. 1215−1221.
- Boodhwania M. Ultrafiltration reduces blood transfusions following cardiac surgery: a meta-analysis. / Boodhwania M., Williamsb K., Babaev A. et al. // Eur. J. Cardiothorac. Surg. 2006. — Vol. 30. — P. 892−897.
- Boshkov L.K. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. / Boshkov L.K., Kirby A., Shen I., Ungerleider R.M. // Ann. Thorac. Surg. 2006. — Vol. 81. — P. 2355−2359.
- Boyle E.M. Endothelial cell injury in cardiovascular surgery: the procoagulant response. Boyle E.M., Verrier E.D., Spiess B.D. // Ann. Thorac. Surg. 1996. — Vol. 62. — P. 1549−1557
- Brass L.F. Thrombin and platelet activation. / Brass L.F. // Chest. 2003. -Vol. 124.-P. 18S-25S.
- Breuer T. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. / Breuer T., Martin K., Wilhelm M. et al. // Eur. J. Cardiothorac. Surg. 2009. — Vol. 35. — P. 167−171.
- Brister S.J. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? / Brister S.J., Ofosu F.A., Buchanan M.R. // Thromb. Haemost. -1993. Vol. 70. — P. 259−262.
- Brown N.J. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. / Brown N.J., Nadeau J.H., Vaughan D.E. // Thromb. Haemost. 1997. — Vol. 77. — P. 522−525.
- Bruce D. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. / Bruce D., Nokes T.J.C. // Critical Care. 2008. — Vol. 12. -R105.
- Bruda N.L. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. / Bruda N.L., Hurlbert B.J., Hill G.E. // Clin. Sci. (Lond). 1998. — Vol. 94. — P. 505−509.
- Bull D. Aprotinin and preservation of myocardial function after ischemia-reperfiision injury. / Bull D., Maurer J. // Ann. Thorac. Surg. 2003. — Vol. 75. — P. S735−739.
- Bulutcu F.S. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination? / Bulutcu F.S., Ozbek U., Polat B. et al. // Paediatr. Anaesth. 2005. — Vol. 15. -P. 41—46.
- Butler J. Inflammatory response to cardiopulmonary bypass. / Butler J., Rocker G.M., Westaby S. // Ann. Thorac. Surg. 1993. — Vol. 55. — P. 552−559.
- Cabrol C. Complete replacement of the ascending aorta with reimplantation of the coronary arteries: new surgical approach. / Cabrol C., Pavie A., Gandjbakheh I. et al.// J. Thorac. Cardiovasc. Surg. 1981. — Vol. 81. — P. 309−315.
- Campbell E.J. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. / Campbell E.J., O’Byrne V., Stratford P.W. // ASAIO J. 1994. — Vol. 40. — P. M853−857.
- Carlstrom A.-S. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. / Carlstrom A.-S., Lieden K., Bjork I. // Thromb. Res. 1977. — Vol. 11. — P. 785−797.
- Carrel T.P. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. / Carrel T.P., Schwanda M., Vogt P.R. et al. // Ann. Thorac. Surg. 1998. — Vol. 66. — P. 153−158.
- Carton T.W. Elastic properties of single elastic fibres. / Carton T.W., Dainauskas J., Ckark J.W. // J. Appl. Physiol. 1962. — Vol. 17. — P. 547−551.
- Casati V. Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques. / Casati V., Gerli C., Franco A. et al. // Anesthesiology. 2001. — Vol. 95. — P. 1103−1109.
- Castaman G. Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. / Castaman G. // Blood Transfus. 2008. — Vol. 6 (Suppl 2). — P. s39−44.
- Chalmers E.A. Neonatal coagulation problems. / Chalmers E.A. // Arch. Dis. Child. Fetal. Neonatal. Ed. 2004. — Vol. 89. — P. F475-F478.
- Chambers L.A. Transfusion patterns in pediatric open heart surgery. / Chambers L.A., Cohen D.M., Davis J.T. // Transfusion. 1996. — Vol. 36. P. 150 154.
- Chan A.K. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. / Chan A.K., Leaker M., Burrows F.A. et al. // Thromb. Haemost. 1997. — Vol. 77. — P. 270−277.
- Chandler W.L. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. / Chandler W.L., Fitch J.C.K., Wall M.H. et al. // Thromb. Haemost. 1995. — Vol.74.- P. 1293−1297.
- Chauhan S. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. / Chauhan S., Kumar B.A., Rao B.H. et al. // Ann. Thorac. Surg. 2000. — Vol. 70. — P. 1308−1312.
- Chauhan S. Dose comparison of tranexamic acid in pediatric cardiac surgery. / Chauhan S., Bisoi A., Kumar N. et al. // Asian. Cardiovasc. Thorac. Ann. -2004.-Vol. 12.-P. 121−124.
- Chauhan S. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. / Chauhan S., Das S.N., Bisoi A. et al. // J. Cardiothorac. Vase. Anesth. 2004. — Vol. 18. — P. 141−143.
- Chung J.H. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. / Chung J.H., Gikakis N., Rao A.K. // Circulation. 1996. — Vol. 93. — P. 2014−2018.
- Cicek S. Topical use of aprotinin in cardiac surgery. / Cicek S., Tatar H., Demirklc U., Kuralay E. // J. Thorac. Cardiovasc. Surg. 1995. — Vol. 110. — P. 568−569.
- Cicek S. Topical aprotinin in cardiac operations: a note of caution. / Cicek S., Theodoro D.A. // Ann. Thorac. Surg. 1996. — Vol. 61. — P. 1039−1040.
- Codispoti M. Individualized heparin and protamine management in infants and children undergoing cardiac operation. / Codispoti M., Ludman C.A., Simpson D., Mankad P. S. // Ann. Thorac. Surg. 2001. — Vol. 71. — P. 922−927.
- Codispoti M. Significant merits of a fibrin sealant in the presence of coagulopathy following paediatric cardiac surgery: randomised controlled trial. / Codispoti M., Mankad P. S. // Eur. J. Cardiothorac. Surg. 2002. — Vol. 22. — P. 200−205.
- Coleman R.W. Contact system: a vascular biology modulator with profibrinolytic, anticoagulant, antiadhesive and proinflammatory attributes. / Coleman R.W., Schmaier A.H. // Blood. 1997. — Vol. 90. — P. 3819−3843.
- Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. // Thromb. Haemost. 1980. — Vol. 43. — P. 77−89.
- Collen D. Activation of plasminogen by pro-urokinase. II. Kinetics. / Collen D., Zamarron C., Blaber M. et al. // J. Biol. Chem. 1986. — Vol. 261. — P. 12 591 266.
- Comunale M.E. Significance of D-dimer concentration during and after cardiopulmonary bypass. / Comunale M.E., Carr J.M., Moorman R.M. et al. // J. Cardiothorac. Vase. Anesth. 1996. — Vol. 10. — P. 477−481.
- Corby D.G. The effects of antenatal drug administration on aggregation of platelets of newborn infants. / Corby D.G., Schulman I. // J. Pediatr. 1971. — Vol. 79.-P. 307−313
- Corrigan J.J. Factor II (prothrombin) levels in cord blood: Correlation of coagulant activity with immunoreactive protein. / Corrigan J.J., Krye J.J. // J. Pediatr. 1980. — Vol. 97. — P. 979−983.
- CoStasis Multi-center Collaborative Writing Committee. A novel collagenbased composite offers effective hemostasis for multiple surgical indications: Results of a randomized controlled trial. // Surgery. 2001. — Vol. 129. — P. 445 450.
- Costello J.M. Aprotinin reduces operative closure time and blood product use after pediatric bypass. / Costello J.M., Backer C.L., de Hoyos A. et al. // Ann. Thorac. Surg. 2003. — Vol. 75. — P. 1261−1266.
- Coughlin S.R. Protease-activated receptors in vascular biology. / Coughlin S.R. // Thromb.Haemost. 2003. — Vol. 86. — P.298−307.
- Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. / Coughlin S.R. // J. Thromb. Haemost. 2005. — Vol. 3. — P. 1800 — 1814.
- Crowley R. Aprotinin decreases ischemic damage during coronary revascularization. / Crowley R., Cabral H.J. // J. Card. Surg. 2005. — Vol. 20. — P. 519−523.
- D’Ambra M.N. Aprotinin in primary valve replacement and reconstruction: a muiticenter, double-blind, placebo-controlled trial. / D’Ambra M.N., Akins C.W., Blackstone E.H. et al. // J. Thorac. Cardiovasc. Surg. 1996. — Vol. 112. — P. 1081−1089.
- Davie E.W. The coagulation cascade: initiation, maintenance, and regulation. / Davie E.W., Fumikawa K., Kisiel W. // Biochemistry. 1991. — Vol. 30. — P. 10 363−10 370.
- Davies M.J. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. / Davies M.J., Allen A., Kort H., et al. // Ann. Thorac. Surg. 1997. — Vol. 63. — P. 497−503.
- Day J.R. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR-1) by intravenous aprotinin during cardiothoracic surgery. / Day J.R., Punjabi P.P., Randi A.M. et al. // Circulation. 2004. — Vol. 110. — P. 2597−2600.
- Day J.R. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. / Day J.R., Taylor K.M., Lidington E.A. et al. // J. Thorac. Cardiovasc. Surg. 2006.- Vol. 131. — P. 21−27.
- D’Errico C.C. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. / D’Errico C.C., Shayevitz J.R., Martindale S.J. et al.//Anesth. Analg. 1996. — Vol. 83. — P. l 193−1199.
- Despotis G.J. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. / Despotis G.J., Joist J.H., Joiner-Maier D. et al. // Ann. Thorac. Surg. 1995.-Vol. 59.-P. 106−111.
- Despotis G.J. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. / Despotis G.J., Avidan M.S., Hogue C.W. // Ann. Thorac. Surg.-2001. Vol. 72.-P. SI821−1831.
- Devbhandari M.P. Acute intraoperative malfunction of aortic valve due to surgical glue. / Devbhandari M.P., Chaudhery Q., Duncan A.J. // Ann. Thorac. Surg. 2006. — Vol. 81. — P. 1499−1500.
- Dietrich W. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. / Dietrich W., Spannagl M., Jochum M. et al. // Anesthesiology. 1990. — Vol. 73. P. 11 191 126.
- Dietrich W. Cardiac surgery and the coagulation system. // Curr. Opin. Anesth. 2000. — Vol. 13. — P. 27−34.
- Draaisma A.M. Phosphorylcholine coating of bypass systems used for young infants does not attenuate the inflammatory response. / Draaisma A.M., Hazekamp M.G., Anes N. et al. // Eur. J. Cardiothorac. Surg. 2000. — Vol. 18. — P. 602−606.
- Dube B. Hemostatic parameters in newborn-I. Effect of gestation and rate of intrauterine growth. / Dube B., Dube R.K., Bhargava V. et al. // Thromb. Haemost. 1986. Vol. 55. — P. 47−50.
- Durandy Y. Perfusionist strategies for blood conservation in pediatric cardiac surgery. / Durandy Y. // World J. Cardiol. 2010. — Vol. 26. — P. 27−33.
- Durgut K. The cerebroprotective effects of pentoxifylline and aprotinin during cardiopulmonary bypass in dogs. / Durgut K., Hosgor K., Gormus N. et al. // Perfusion. 2004. — Vol. 19. — P. 101−106.
- Eaton D. Biological activity of human trombopoietin (TPO), the mpl ligand, TPO variants and the chromosomal localization of PTO. / Eaton D., Gurney A., Malloy B. et al. // Blood. 1994. — Vol. 84. — P. 241−246.
- Eaton M.P. Hemispheric infarction in a patient with an undiagnosed vasculopathy treated with aprotinin. / Eaton M.P., Alfieris G.M. // J. Cardiothorac. Vase. Anesth. 2004. — Vol. 18. — P. 194−196.
- Eaton M.P. AntifYbrinolytic therapy in surgery for congenital heart disease. / Eaton M.P. // Anesth. Analg. 2008. — Vol. 106. — P. 1087−1100.
- Edmunds L.H. Why cardiopulmonary bypass makes people sick: strategies to control the blood-synthetic interface. // B kh.: Karp R.B., Laks H., Wechsler A.S., eds. Advances in cardiac surgery. Vol. 6. Chicago, IL: Mosby-Year Book, 1995.-P. 131−167.
- Edmunds L.H. Thrombin during cardiopulmonary bypass / Edmunds L.H., Colman R.W. // Ann. Thorac. Surg. 2006. — Vol. 82. — P. 2315−2322.
- Edmunds L.H. Bleeding that won’t stop. / Edmunds L.H. Jr., Colman R.W. // Ann Thorac Surg. 2008. — Vol. 85. — P. 1153−1154.
- Edwards R.M. Parameters of thromboelastography in healthy newborns. / Edwards R.M., Naik-Mathuria B.J., Gay A.N. et al. // Am. J. Clin. Pathol. 2008. -Vol. 130.-P. 99−102.
- Egan J. Recombinant activated factor VII in paediatric cardiac surgery. / Egan J., Lammi A., Schell D. et al. // Intensive Care Med. 2004. — Vol. 30. — P. 682−685.
- Ekert H. Hemostasis in cyanotic congenital heart disease. / Ekert H., Gilchrist G.S., Stanton R., Hammerand D. // J. Pediatr. 1970. — Vol. 76. — P. 227−230.
- Elliott M.J. Ultrafiltration and modified ultrafiltration in pediatric open heart operations. / Elliott M.J. // Ann. Thorac. Surg. 1993. — Vol. 56. — P. 1518−1522.
- Engelman R.M. Influence of cardiopulmonary bypass perfusion temperature on neurologic and hematologic function after coronary artery bypass grafting. / Engelman R.M., Pleet A.B., Rousou J.A. et al. // Ann. Thorac. Surg. 1999. — Vol. 67.-P. 1547−1555.
- Englberger L. Aprotinin in coronary operation with cardiopulmonary bypass: does «low-dose» aprotinin inhibit the inflammatoryresponse? / Englberger L., Kipfer B., Berdat P.A. et al. // Ann. Thorac. Surg. 2002. — Vol. 73. — P. 18 971 904.
- Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery. // Am. J. Health. Syst. Pharm. 2005. — Vol. 62. — P. S9-S14.
- Erdogan M. Protective effect of aprotinin against lung damage in patients undergoing CABG surgery. / Erdogan M., Kalaycioglu S., Iriz E. // Acta. Cardiol. 2005. — Vol. 60. — P. 367−372.
- Eren S. The effect of aprotinin on ischemiareperfusion injury in an in situ normothermic ischemic lung model. / Eren S., Esme H., Balci A.E. et al. // Eur. J. Cardiothorac. Surg. 2003. — Vol.23. — P. 60−65.
- Esmon C.T. Role of coagulation inhibitors in inflammation. / Esmon C.T. // Thromb. Haemost. 2001. — Vol. 86. — P. 51−56.
- Fay P.G. Factor VIII structure and function. / Fay P.G. // Thromb. Haemost. -1993.-Vol. 70.-P. 63−67.
- Fergusson D.A. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. / Fergusson D.A., Hebert P.C., Mazer C.D. et al. // N. Engl. J. Med. 2008. — Vol. 358. — P. 2319−2331.
- Ferraris V.A. The platelet thrombin receptor and postoperative bleeding. / Ferraris V.A., Ferraris S.P., Singh A. et al. // Ann. Thorac. Surg. 1998. — Vol. 65. -P. 352−358.
- Fischer J.H. Effects of aprotinin on endotheliumdependent relaxation of large coronary arteries. / Fischer J.H., Steinhoff M. // Eur. J. Cardiothorac. Surg. -2005,-Vol. 28.-P. 801−814.
- Follisa F. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? / Follisa F., Filipponea G., Montalbanoa G. et al. // Interact. CardioVasc Thorac. Surg. 2010. — Vol. 10. — P. 592−596.
- Folman C. Platelets release TPO upon activation: another regulatory loop in thrombocytopoiesis. / Folman C., Linthorst G., van Mourik J. et al. // Thromb. Haemost. 2000. Vol. 83. — P. 923−930.
- Foster D. Human trombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. / Foster D., Specher C., Grant F. et al. // Proc. Natl. Acad. Sci. USA. 1994. — Vol. 91. — P. 13 023−13 027
- Franchini M. Prothrombin complex concentrates: an update. / Franchini M., Lippi G. // Blood Transfus. 2010. — Vol. 8. — P. 149−154.
- Francis C.W. Physiologic regulation and pathologic disorders of fibrinolysis. / Francis C.W., Marder V.J. // Hum. Pathol. 1987. — Vol. 18. — P. 263−274.
- Frederiksen M.C. Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects. / Frederiksen M.C., Bowsher D.J., Ruo T.I. et al. // Clin. Pharmacol. Ther. 1984. — Vol. 35. — P. 387 393.
- Frick P.G. The mechanism of heparin rebound after extracorporeal circulation for open heart surgery. / Frick P.G., Brogli H. // Surg. Gynecol. Obstet. 1966. — Vol. 59. — P. 721−726.
- Friesen R.H. Modified ultrafiltration attenuates dilutional coagulopathy in pediatric open heart operations. / Friesen R.H., Campbell D.N., Clarke D.R., Tornabene M.A. // Ann. Thorac. Surg. 1997. — Vol. 64. — P. 1787−1789.
- Fritz H. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. / Fritz H., Wunderer G. // Arzneimittelforschung. 1983. -Vol. 33.-P. 479194.
- Frumento R.J. Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. / Frumento R.J., O’Malley C.M.N., Bennett-Guerrero E. // Ann. Thorac. Surg. 2003. — Vol. 75. — P.479−484.
- Furnary A.P. Does aprotinin increase the risk of renal failure in cardiac surgery patients? / Furnary A.P., Hiratzka L.F., Wu Y. et al. // Circulation. 2006. -Vol. 114. — A3347.
- Gates R. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients. / Gates R., Yost P., Parker B. // Artif. Organs. 2010. — Vol. 34. — P. 667−669.
- Gettins PGW. Serpin structure, mechanism and function. // Chem. Rev. -2002.-Vol. 102.-P. 4751−4803.
- Ginsburg D. von Willebrand disease: a data base of point mutation, insertions and deletions. / Ginsburg D., Sadler J.E. // Thromb. Haemost. 1993. -Vol. 69.-P. 177−184.
- Glickman M. A polymeric sealant inhibits anastomotic suture hole bleeding more rapidly than gelfoam/thrombin: results of a randomized controlled trial. / Glickman M., Gheissari A., Money S. et al. // Arch. Surg. 2002. — Vol. 137. — P. 326−332.
- Golab H.D. Intraoperative cell salvage in infants undergoing elective cardiac surgery: a prospective trial. / Golab H.D., Scohy T.V., de Jong P.L. et al. // Eur. J. Cardiothorac. Surg. 2008. — Vol. 34. — P. 35−4-359.
- Golab H.D. Specific requirements for bloodless cardiopulmonary bypass in neonate and infants: a review. / Golab H.D., Nakkenberg J.J.M., Bogers A.J.J. // Perfusion. 2010. — Vol. 25. — P. 237−243.
- Goodnough L.T. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. / Goodnough L.T., Kuter D.J., McCullough J. et al.//Blood. 2001.-Vol. 98. — P.1346−1351.
- Gram J. Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increase the risk of post-surgical bleeding. / Gram J., Janetzko T., Jespersen J. et al. // Thromb. Hemost. 1990. — Vol. 63. — P. 241−245.
- Gravlee G.P. Update on cardiopulmonary bypass. // Curr. Opin. Anesth. -2001. Vol. 14.-P. 11−16.
- Greenberg C.S. Factor XHIa formation promoted by complexing of a-thrombin, fibrin, and plasma factor XIII. / Greenberg C.S., Achyuthan K.E., Fenton II J. W. // Blood. 1987. — Vol. 69. — P. 867−871.
- Greilich P.E. Aprotinin but not e-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation. / Greilich P.E., Okada K., Latham P. et al. // Circulation. 2004. — Vol. 104. — P. 1265−1269.
- Grocott H.P. The effects of aprotinin on outcome from cerebral ischemia in the rat. / Grocott H.P., Sheng H., Miura Y. et al. // Anesth. Analg. 1999. — Vol. 88.-P. 1−7.
- Gross S.J. Hemostasis in the premature infant. / Gross S.J., Stuart M.J. // Clin. Perinatol. 1977. — Vol. 4. — P. 259−304.
- Gruenwald C.E. Reconstituted fresh whole blood improves clinical outcomes compared with stored component blood therapy for neonates undergoing cardiopulmonary bypass for cardiac surgery: a randomized controlled trial. /309
- Gruenwald C.E., McCrindle B.W., Crawford-Lean L. et al. // J. Thorac. Cardiovasc. Surg. 2008. — Vol. 136. — P. 1442−1449.
- Gurbuz A.T. Impact of ultrafiltration on blood use for atrial septal defect closure in infants and children. / Gurbuz A.T., Novick W.M., Pierce C.A., Watson D.C. // Ann. Thorac. Surg. 1998. — Vol. 65. — P. 1105−1109.
- Guzzetta N.A. The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis. / Guzzetta N.A., Evans F.M., Rosenberg E.S. et al. // Anesth. Analg. 2009/ - Vol. 108. — P. 448−455.
- Hagberg R.C. Improved intraoperative management of anastomotic bleeding during aortic reconstruction: results of a randomized controlled trial. / Hagberg R.C., Safi H.J., Sabik J. et al. // Am. Surg. 2004. — Vol. 70. — P. 307−311.
- Hamulyak K. Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns. / Hamulyak K., Nieuwenhuizen W., Devilee P.P., Hemker H.C. //Thromb. Res. 1983. — Vol. 32. — P. 301−310.
- Harmon D.C. The effect of aprotinin on hypoxia-reoxygenation-induced changes in neutrophil and endothelial function. / Harmon D.C., Lan W., Shorten G. // Eur. J. Anaesthesiol. 2004. — Vol. 21. — P. 973−979.
- Harmon D.C. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. / Harmon D.C., Ghori K.G., Eustace N.P. et al. // Can. J. Anaesth. 2004. -Vol. 51.-P. 1002−1009.
- Hathaway W.E. The bleeding newborn. / Hathaway W.E. // Semin. Hematol. 1975.-Vol. 12.-P. 175−188.
- Hauert J. Prourokinase in the euglobulin fractions. / Hauert J., Bachmann F. // Thromb. Haemost. 1985. — Vol. 54. — P. 122
- Heindel S.W. Fatal thrombosis associated with a hemi-Fontan procedure, heparin-protamine reversal, and aprotinin. Heindel S.W., Mill M.R., Freid E.B. et al. // Anesthesiology. 2001. — Vol. 94. — P. 369−371.
- Hellstern P. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. / Hellstern P., Halbmayer W. M, Kohler M. et al. // Thromb. Res. 1999. — Vol. 95. — S3−6.
- Henderson L.M. Assembly of contact-phase factors on the surface of the human neutrophil membrane. / Henderson L.M., Figueroa C.D., Muller-Esteral W., Bhoola K.D. // Blood. 1994. — Vol. 84. — P. 474−482.
- Hendrikx M. Na+/H±exchange inhibition and aprotinin administration: promising tools for myocardial protection during minimally invasive CABG. / Hendrikx M., Rega F., Jamaer L. et al. // Eur. J. Cardiothorac. Surg. 2001. — Vol. 19.-P. 633−639.
- Henriksson P. Fibrin-stabilizing factor (factor XIII) in the fetus and the newborn infant. / Henriksson P., Hedner U., Nilsson I.M. et al. // Pediatr. Res. -1974.-Vol. 8.-P. 789−791.
- Henriksson P. Haemostasis defects in cyanotic congenital heart disease. / Henriksson P., Varendh G., Lundstrom N.R. // Br. Heart. J. 1979. — Vol.41. — P. 23−27.
- Hermans J.M. Interaction of activated protein C with serpins. / Hermans J.M., Stone S.R. // Biochem. J. 1993. — Vol. 295. — P. 239−245.
- Herynkopf F. Aprotinin in children undergoing correction of congenital heart defects. A double-blind pilot study. / Herynkopf F., Lucchese F., Pereira E. et al. // J. Thorac. Cardiovasc.Surg. 1994. — Vol. 108. — P. 517−521.
- Hibino N. Preoperative autologous blood donation for cardiac surgery in children. / Hibino N., Nagashima M., Sato H. et al. // Asian. Cardiovasc. Thorac. Ann. 2008. — Vol. 16. — P. 21−24.
- Hill G.E. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. / Hill G.E., Pohorecki R., Alonso A. et al. // Anesth. Analg. 1996. — Vol. 83. — P. 696−700.
- Himmelfarb J. Effects of aprotinin on complement and granulocyte activation during ex vivo hemodialysis. / Himmelfarb J., Holbrook D., McMonagle E. // Am. J. Kidney. Dis. 1994. — Vol. 24. — P. 901−906.
- Hornykewycz S. Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants. / Hornykewycz S., Odegard K.C., Castro R.A. et al. // Paediatr. Anaesth. 2009. -Vol. 19.-P. 854−861.
- Huang H. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. / Huang H., Ding W., Su Z., Zhang W. // J. Thorac. Cardiovasc.Surg. 1993. — Vol. 106. — P. 11−18.
- Hunt B.J. Activation of coagulation and fibrinolysis during cardiothoracic operations. / Hunt B.J., Parratt R.N., Segal H.C. et al. // Ann. Thorac. Surg. 1998. -Vol. 65.-P. 712−718.
- Ichinose A. Lokalization of the binding site of tissue-type plasminogen activator to fibrin. / Ichinose A., Takio K., Fujikawa K. // J. Clin. Invest. 1986. -Vol. 78.-P. 163−169.
- Ichinose A. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. / Ichinose A., Fujikawa K., Suyama T. // J. Biol. Chem. -1986. Vol. 261. — P. 3486−3489.
- Jacobs J.P. Expanded PTFE membrane to prevent cardiac injury during resternotomy for congenital heart disease. / Jacobs J.P., Iyer R.S., Weston J.S. et al. // Ann. Thorac. Surg. 1996. — Vol. 62. — P. 1778−1782.
- Jaggers J. Infant cardiopulmonary bypass: a procoagulant state./ Jaggers J., Neal M., Smith P.K. et al. // Ann. Thorac. Surg. 1999. — Vol. 68. — P. 513−520.
- Jaggers J. Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies. / Jaggers J., Lawson J.H. // Ann. Thorac. Surg. 2006. -Vol. 81.-P. 2360−2366.
- Jancen P.G. Reduction in prime volume attenuates the hyperdynamic response after cardiopulmonary bypass. / Jancen P.G., te Velthuis H., Bulder E.R. et al. // Ann. Thorac. Surg. 1995. — Vol. 60. — P. 544−550.
- Jaquiss R.D. Safety of aprotinin use and re-use in pediatric cardiothoracic surgery. / Jaquiss R.D., Ghanayem N.S., Zacharisen M.C. et al. // Circulation. -2002.-Vol. 106. P. 190−194.
- Jenkins K.J. Risk adjustment for congenital heart surgery: the RACHS-1 method. // Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Arm. 2004. -Vol.7.-P. 180−184.
- Jesty J. The kinetics of formation and dissociation of the bovine thrombin-antithrombin III complex. / Jesty J. // J.Biol.Chem. 1979. — Vol. 254. — P 1 004 410 050.
- Kaminski K.A. Oxidative stress and neutrophil activation—the two keystones of ischemia/reperfusion injury. / Kaminski K.A., Bonda T.A., Korecki J. et al. // Int. J. Cardiol. 2002. — Vol. 86. — P. 41−59.
- Kane W.H. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders / Kane W.H., Davie E.W.//Blood. 1988. — Vol. 71.-P. 539−555.
- Kang H.M. The kinetics of plasmin inhibition by aprotinin in vivo. / Kang H.M., Kalnoski M.H., Frederick M. et al. // Thromb. Res. 2005. — Vol. 115. — P. 327−340.
- Karimi M. Mechanical aortic valve malfunction: an intraoperative BioGlue complication. / Karimi M., Kerber R.E., Everett J.E. // J. Thorac. Cardiovasc. Surg. 2005. — Vol. 129. — P. 1442−1443.
- Karitsky D. Fibrinogen turnover in the premature infant with and without idiopathic respiratory distress syndrome. / Karitsky D., Kleine N., Pningsheim W., Kunzer W. // Acta Paediatr. Scand. 1971. — Vol. 60. — P. 465−470.
- Karkouti K. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. / Karkouti K., Beattie W.S., Dattilo K.M. et al. // Transfusion. 2006. — Vol. 46. — P. 327−338.
- Karlsson M. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. / Karlsson M., Ternstrom L., Hyllner M. et al. // Thromb. Haemost. 2009. — Vol. 102. — P. 137−144.
- Karsies T.J. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience. / Karsies T.J., Nicol K.K., Galantowicz M.E. // Ann. Thorac. Surg. 2010. — Vol. 89. — P.570−576
- Kaushansky K. The molecular mechanisms that control thrombopoiesis. / Kaushansky K. // Clin. Invest. 2005. — Vol. 114. — P. 3339−3347.
- Kazui T. Role of biologic glue repair of proximal aortic dissection in the development of early and midterm redissection of the aortic root. / Kazui T., Washiyama N., Bashar A.H. et al. // Ann. Thorac. Surg. 2001. — Vol. 72. — P. 509 514.
- Kern F.H. Coagulation defects in neonates during cardiopulmonary bypass. / Kern F.H., Morana N.J., Sears J.J., Hickey P.R. // Ann. Thorac. Surg. 1992. -Vol. 54.-P. 541−546.
- Kern F.H. Cardiopulmonary bypass: techniques and effects. / Kern F.H., Schulman S.R., Greeley W.J. // B kh.: Greeley WJ, ed. Perioperative management of the patient with congenital heart disease. Baltimore: Williams & Wilkins, 1996. — P. 67−120.
- Kertai M.D. Aprotinin and perioperative complications in cardiac surgery. / Kertai M.D., Varga K.S., Royston D. et al. // J. Cardiovasc. Surg. (Torino). 2007.- Vol. 48. P. 761−772.
- Kestin A.S. The platelet function defect of cardiopulmonary bypass. / Kestin A.S., Valeri C.R., Khuri S.F. et al. // Blood. 1993. — Vol. 82. — P. 107−117.
- Khalil P.N. Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass. / Khalil P.N., Ismail M., Kalmar P. et al. // Thromb. Haemost. 2004. — Vol. 92. — P. 568−574.
- Khan M.H. Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass. / Khan M.H., Gikakis N., Miyamoto S. et al. // Ann. Thorac. Surg. 1999. — Vol. 68. — P. 473−478.
- Khan T.A. Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. / Khan T.A., Bianchi C., Voisine P. et al. // J. Thorac. Cardiovasc. Surg. 2004. — Vol. 128. — P. 602−628.
- Khan T.A. Aprotinin preserves cellular junctions and reduces myocardial edema after regional ischemia and cardioplegic arrest. / Khan T.A., Bianchi C., Araujo E. et al. // Circulation. 2005. — Vol. 112. — P. 1196−1201.
- Kheirabadi B.S. Comparative study of the efficacy of the common topical hemostatic agents with fibrin sealant in a rabbit aortic anastomosis model. / Kheirabadi B.S., Field-Ridley A., Pearson R. et al. // J. Surg. Res. 2002. — Vol. 106. — P. 99−107.
- Kher A. Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion. / Kher A., Meldrum K.K., Hile K.L. et al. // J. Thorac. Cardiovasc. Surg. 2005. — Vol. 130.- P. 662−669.
- Kjaergard H. Controlled clinical studies of fibrin sealant in cardiothoracic surgery. / Kjaergard H., Fairbrother J. // Eur. J. Cardiothorac. Surg. 1996. — Vol. 10. — P. 727−733
- Kluft C. Role of the contact system in fibrinolysis. / Kluft C., Dooijewaard G., Emeis J.J. // Sem. Thromb. Hemost. 1987. — Vol. 13. — P. 50−68.
- Knobl P.N. The protein C system in patients undergoing cardiopulmonary bypass. / Knobl P.N., Zilla P., Fasol R. et al. // J. Thorac. Cardiovasc. Surg. -1987.-Vol. 94.-P. 600−605
- Knudsen L. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery. / Knudsen L., Hasenkam M.J., Kure H.H. et al. // Thromb. Res. 1996. — Vol. 84. — P. 45−54.
- Koch C.G. Red cell transfusion is associated with an increased risk for postoperative atrial fibrillation. / Koch C.G., Li L., Van Wagoner D.R. et al. // Ann. Thorac. Surg. 2006. — Vol. 82. — P. 1747−1756.
- Koksal C. Attenuation of acute lung injury following lower limb ischemia/reperfusion: the pharmacological approach. / Koksal C., Bozkurt A.K., Ustundag N. et al. /'/' J. Cardiovasc. Surg. 2006. — Vol. 47. — P. 445−449.
- Kolindewala J.K. Hemostatic parameters in newborn-Il. Sequential study during the first four weeks of life. / Kolindewala J.K., Dube B., Bhargava V. et al. // Thromb. Haemost. 1986. — Vol. 55. — P. 51−53.
- Konertz W.F. Reducing the incidence and severity of pericardial adhesions with a sprayable polymeric matrix. / Konertz W.F., Kostelka M., Mohr F.W. et al. // Ann. Thorac. Surg. 2003. — Vol. 76. — P. 1270−1274.
- Koster A. High-dose aprotinin effectively reduces blood loss during on-pump coronary artery bypass grafting with bivalirudin anticoagulation. / Koster A., Buz S., Krabatsch T. et al. // J. Thorac. Cardiovasc. Surg. 2008. — Vol. 135. — P. 685−687.
- Kraut E. Uber die Inaktivierung des Kallikreins (VI. Mitteilung uber dieses Kreislaufhormon). / Kraut E., Frey K., Werle E. // Hoppe. Seylers. Z. Physiol. Chem.- 1930.-Vol. 192.-P. 1−21.
- Kunitz M. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor, and an inhibitor-trypsin compound. / Kunitz M., Northrop J.H. // J. Gen. Physiol. 1936. — Vol. 19. — P. 991−1007.
- Kuter D.J. Thrombopoietin therapy increases platelet yields in healthy platelet donors. / Kuter D.J., Goodnough L.T., Romo J. et al. // Blood. 2001. -Vol. 98.-P. 1339- 1345.
- Kuter D.J. New thrombopoietic growth factors. / Kuter DJ // Clinical Lymphoma & Myeloma 2009. — Vol. 9. — Suppl. 3. — P. S347-S356.
- Lacour-Gayet F. The Aristotle score: a complexity-adjusted method to evaluate surgical results. / Lacour-Gayet F., Clarke D., Jacobs J. et al. // Eur. J. Cardiothorac. Surg. 2004. — Vol. 25. — P. 911−924.
- Laffey J. The systemic inflammatory response to cardiac surgery. / Laffey J., Boylan J., Cheng D. // Implications for the anesthesiologist. Anesthesiology. -2002.-Vol. 97.-P. 215−252.
- Lalezari S. The outflow tract in transposition of the great arteries: an anatomic and morphologic study. / Lalezari S., Mahtab E.A.F., Bartelings M.M. et al. // Ann. Thorac. Surg. 2009. — Vol. 88. — P. 1300−1305.
- Lambers J.W.J. Activation of human endothelial cell-type plasminogen activator inhibitor by negatively charged phospholipids. / Lambers J.W.J., Cammenga M., Konig B.W. et al.// J. Biol. Chem. 1987. — Vol. 262. — P. 1 749 217 496.
- Landis R.C. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. / Landis R.C., Asimakopoulos G., Poullis M. et al. // Ann. Thorac. Surg. 2001. — Vol. 72. — P. 2169−2175.
- Lang T. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. / Lang T., Johanning K., Metzler H. et al. // Anesth. Analg. 2009. — Vol. 108. — P 751−758.
- Langer B.G. Deglycosylation of fibrinogen accelerates polymerization and induced aggregation of fibrin fibers. / Langer B.G., Weisel J.W., Dinauer P.A. et al.//J. Biol. Chem. 1988.-Vol. 263.-P. 15 056−15 063.
- Lappegard K.T. Artificial surface induced cytokine synthesis: effect of heparin coating and complement inhibition. / Lappegard K.T., Fung M., Bergseth G. et al. // Ann. Thorac. Surg. 2004. — Vol. 78. — P. 38−45.
- Lazar H.L. Aprotinin decreases ischemic damage during coronary revascularization. / Lazar H.L., Bao Y., Tanzillo L. et al. // J. Card. Surg. 2005. -Vol. 20.-P. 519−523.
- Lee R. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. / Lee R., Tsuji K., Lee S.R. et al. // J. Neurosci. 2004. — Vol. 24. — P. 671−678.
- LeMaire S.A. BioGlue surgical adhesive impairs aortic growth and causes anastomotic strictures. / LeMaire S.A., Schmittling Z.C., Coselli J.S. et al. // Ann. Thorac. Surg. 2002. — Vol. 73. — P. 1500−1506.
- LeMaire S.A. The threat of adhesive embolization: BioGlue leaks through needle holes in aortic tissue and prosthetic grafts. / LeMaire S.A., Carter S.A., Won T. et al. // Ann. Thorac. Surg. 2005. — Vol. 80. — P. 106−111.
- Lemmer J.H. Jr. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. / Lemmer J.H. Jr., Stanford W., Bonney S.L. et al. // Ann. Thorac. Surg. 1995. — Vol. 59. — P. 132−136.
- Lemmer J.H. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. / Lemmer J.H., Dilling E.W., Morton J.R. et al. // Ann. Thorac. Surg. 1996. — Vol. 62. — P. 1659−1668.
- Levin E.G. Stimulation and desensitization of tissue-plasminogen activator release from human endothelial cells. / Levin E.G., Santell L. // J. Biol. Chem. -1988. Vol. 263. — P. 9360 -9365.
- Levy J.H. Inflammatory response to cardiopulmonary bypass. / Levy J.H., Tanaka K.A. // Ann. Thorac. Surg. 2003. — Vol. 75. — P. S715−720.
- Li J.M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. / Li J.M., Shah A.M. // Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004. — Vol. 287. — P. R1014−1030.
- Li S. Combination of acute preoperative plateletpheresis, cell salvage, and aprotinin minimizes blood loss and requirement during cardiac surgery. / Li S., Ji H., Lin J. et al. // J. Extra. Corpor. Technol. 2005. — Vol. 37. — P. 9 -14.
- Lijnen H.R. Activation of plasminogen by pro-urokinase. I. Mechanism. / Lijnen H.R., Zamarron C., Blaber M. et al. // J. Biol. Chem. 1986. — Vol. 261. -P. 1253−1258.
- Lill M.C. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. / Lill M.C., Perloff J.K., Child J.S. // Am. J. Card. 2006. — Vol. 98. — P. 254−258.
- Lippi G. Vitamin K in neonates: facts and myths. / Lippi G., Franchini M. // Blood Transfus. 2011. — Vol. 9. — P. 4−9.
- Low D. Released protease nexin regulates cellular binding, internalization and degradation of serine proteases. / Low D., Baker J., Koonce W., Cunningham D. // Proc. Natl. Acad. Sci. USA. 1981. — Vol. 78. — P. 2340−2344.
- Lumsden A.B. Prospective randomized study evaluating an absorbable cyanoacrylate for use in vascular reconstructions. / Lumsden A.B., Heyman E.R. // J. Vase. Surg. 2006. — Vol. 44. — P. 1002−1009.
- Mangano D.T. Cardiovascular morbidity and CABG surgery a perspective: epidemiology, costs, and potential therapeutic solutions. // J. Card. Surg. — 1995. -Vol. 10.-P. 366−368.
- Mangano D.T. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. / Mangano D.T., Miao Y., Vuylstekc A. et al. // JAMA. 2007. — Vol. 297. — P. 471−479.
- Manno C.S. Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. / Manno C.S., Hedberg K. W, Kim H.C. et al. // Blood. 1991. — Vol. 77. — P. 930−936.
- Manrique A. The association of renal dysfunction and the use of aprotinin in patients undergoing congenital cardiac surgery requiring cardiopulmonary bypass. / Manrique A., Jooste E.H., Kuch B.A. et al. // Anesth. Analg. 2009. — Vol. 109. -P. 45−52.
- Marder V.J. Hight molecular weight derivates of human fibrinogen produced by plasmin (I). Physicochemical and immunological characterization. Marder V.J., Shulman N.R., Carrol W.R. // J.Biol.Chem. 1969. — Vol. 244. — P. 2111−2119.
- Martinez J. Functional and metabolic propertits of asialofibrinogen. / Martinez J., Palascak J., Peters C. // J. Lab. Clin. Med. 1977. — Vol. 98. — P. 367 377
- Martini W.Z. Acute changes in fibrinogen metabolism and coagulation after hemorrhage in pigs. / Martini W.Z., Chinkes D.L., Pusateri A.E. et al. // Am. J. Physiol. Endocrinol. Metab. 2005. — Vol. 289. — P. E930−934.
- Mathias M.A. Aprotinin improves pulmonary function during reperfusion in an isolated lung model. / Mathias M.A., Tribble C.G., Dietz J.F. et al. // Ann. Thorac. Surg. -2000. Vol. 70. — P. 1671−1674.
- Mazer C.D. Vascular injury and thrombotic potential: a note of caution about recombinant factor Vila. / Mazer C.D., Leong-Poi H., Mahoney J. et al. // Seminars in Cardiothoracic and Vascular Anesthesia. 2007. — Vol. 11. — P. 261 -264.
- McCarthy R.J. Aprotinin pretreatment diminished postichemic myocardial contractile dysfunction in dogs. / McCarthy R.J., Tuman K., O’Connor C. et al. // Anesth. Analg. 1999. — Vol.89. — P. 1096−1101.
- McClure P.D. The use of epsilon-aminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease. / McClure P.D., Izsak J. // Anesthesiology. 1974. — Vol. 40. — P. 604−608.
- McEvoy M.D. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. / McEvoy M.D., Reeves S.T., Reves J.G., Spinale F.G. // Anesth. Analg. 2007. — Vol. 105. — P. 949−962.
- McGill N. Mechanical methods of reducing blood transfusion in cardiac surgery: randomised controlled trial. / McGill N., O’Shaughnessy D., Pickering R. et al. // BMJ 2002. — Vol. 324. — P. 1299−1306.
- Meyr D. von Willebrand factor: structure and function. / Meyr D., Girma J.P. // Thromb. Haemost. 1993. — Vol. 70. — P. 99−104.
- Michelson A.D. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. / Michelson A.D., MacGregor H., Barnard M.R. et al. // Thromb. Haemost. 1994. — Vol. 71. — P. 633−640.
- Michelson A.D. Platelet function in the newborn. / Michelson A.D. // Semin. Thromb. Hemost. 1998. — Vol. 24. — P. 507−512.
- Miller B.E. Predicting and treating coagulopathies after cardiopulmonary bypass in children. / Miller B.E., Mochizuki T., Levy J.H. et al. // Anesth. Analg. -1997.-Vol. 85.-P.l 196−1202.
- Miller B.E. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. / Miller B.E., Tosone S.R., Tam V.K. et al. // Ann. Thorac. Surg. 1998. — Vol. 66. — P. 535- 541.
- Miller B.E. Fibrinogen in children undergoing cardiac surgery: is it effective? / Miller B.E., Tosone S.R., Guzzetta N.A. et al. // Anesth. Analg. -2004. Vol. 99. — P. 1341−1346.
- Millner R.W. A new hemostatic agent: initial life-saving experience with Celox (chitosan) in cardiothoracic surgery. / Millner R.W., Lockhart A.S., Bird H., Alexiou C. // Ann. Thorac. Surg. 2009. — Vol. 87. — P. el3−14.
- Minale C. Clinical experience with expanded polytetrafluoroethylene Gore-TexTM surgical membrane for pericardial closure: a study of 110 cases. / Minale C., Nikol S., Hollweg G. et al. // J. Card. Surg. 1988. — Vol. 3. — P. 193−201.
- Mitchell L. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III deficient children. / Mitchell L., Piovella F., Ofosu F., Andrew M. // Blood. 1991. — Vol. 78. — P. 2299−2304
- Miyaji K. Pediatric cardiac surgery without homologous blood transfusion using a miniaturized bypass system in small infants. / Miyaji K., Miyamoto T., Kohira S. et al. // J. Thorac. Surg. 2007. — Vol. 134. — P 284−289.
- Miyaji K. Miniaturized cardiopulmonary bypass system in neonates and small infants. / Miyaji K., Miyamoto T., Kohira S. et al. // Interact. Cardiovasc. Thorac. Surg. 2008. — Vol. 7. — P. 75−79.
- Miyakawa Y. Trombopoietin induces tyrosine phosphorylation of STAT3 and STAT5 in human blood platelets. / Miyakawa Y., Oda A., Druker B. et al. // Blood. 1996. — Vol. 87. — P. 439−446.
- Miyashita T. Hemostatic effects of low-dose protamine following cardiopulmonary bypass. / Miyashita T., Nakajima T., Hayashi Y., Kuro M. // Am.J.Hematol. 2000. — Vol. 62. — P. 112−115.
- Mojcik C.F. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. / Mojcik C.F., Levy J.H. // Ann. Thorac. Surg. 2001. -Vol. 71.-P. 745−754.
- Moller P. Plasma thrombopoietin concentration in response to platelet transfusion therapy. / Moller P., Andersson P., Andersson A., Wadenvik H. // Acta Haematol. 2000. — Vol. 102.-P. 131−134.
- Morton L.F. Collagen polymorphism in the normal and diseased blood vessel wall. Investigation of collagens types I, III and V. / Morton L.F., Barnes M.J. // Atherosclerosis. 1982. — Vol. 42. — P. 41−51.
- Mossinger H. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. / Mossinger H., Dietrich W. // Ann. Thorac. Surg. -1998.-Vol. 65.-P. -45−51.
- Mou S.S. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. / Mou S.S., Giroir B.P., Molitor-Kirsch E.A. et al. // N. Engl. J. Med. 2004. — Vol. 351. — P. 1635−1644.
- Mouton R. Effect of aprotinin on renal dysfunction. / Mouton R., Finch D., Davis I., Zacharowski K. // Lancet. 2008. — Vol. 372. — P. 1543−1544.
- Mugge A. Platelets, endothelium-dependent responses and atherosclerosis. / Mugge A., Forstermann U., Lichtlen P.R. // Ann. Med. 1991. — Vol. 23. — P. 545 550.
- Muntean W. Immunologic studies of prothrombin in newborns. / Muntean W., Petck W., Rosanelli K., Mutz I.D. // Pediatr. Res. 1979. — Vol. 13. — P. 12 621 265.
- Murkin J.M. Attenuation of neurologic injury during cardiac surgery. // Ann. Thorac. Surg. -2001. Vol. 72. — P. S1838-S1844.
- Murphy E.F. The reduced adsorption of lysozyme at the phosphorylcholine incorporated polymer/aqueous solution interface studied by spectroscopic ellipsometry. / Murphy E.F., Keddie J.L., Lu J.R. et al. // Biomaterials. 1999. -Vol. 20.-P. 1501−1511.
- Murugesan C. The efficacy of aprotinin in arterial switch operations in infants. / Murugesan C., Banakal S.K., Garg R. et al. // Anesth. Analg. 2008. -Vol. 107.-P. 783−787.
- Naik S.K. A successful modification of ultrafiltration for cardiopulmonary bypass in children. / Naik S.K., Knight A., Elliott M.J. // Perfusion. 1991. — Vol. 6. — P. 41−50.
- Nakamura M. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia. / Nakamura M., Toombs C.F., Duarte I.G. et al. // Ann. Thorac. Surg. 1998. — Vol. 66. — P. 1216−1223.
- Napoleone C.P. Resternotomy in pediatric cardiac surgery: CoSeal® initial experience. / Napoleone C.P., Oppido G., Angeli E., Gargiulo G. // Interact. CardioVasc. Thorac. Surg. 2007. — Vol. 6. — P. 21−23.
- Napoleone C.P. An observational study of CoSeal for the prevention of adhesions in pediatric cardiac surgery. / Napoleone C.P., Valori A., Crupi G. et al. // Interact. CardioVasc. Thorac. Surg. 2009. — Vol. 9. P. 978−982.
- Ngaage D.L. A cautionary note regarding long-term sequelae of biologic glue. / Ngaage D.L., Edwards W.D., Bell M.R., Sundt T.M. // J. Thorac. Cardiovasc. Surg. 2005. — Vol. 129. — P. 937−938.
- Nossel H.L. A study of coagulation factor levels in women during labour and in their newborn infants. / Nossel' H.L., Lanzkavsky P., Levy S. et al. // Thromb. Diath. Haemorrh. 1966. — Vol. 16. — P. 185−197.
- O’Connell K.A. Thromboembolic adverse events after use of recombinant human coagulation factor Vila. / O’Connell K.A., Wood J.J., Wise R.P. et al. // JAMA. 2006. — Vol. 295. — P.293−298.
- Okamoto Y. Effects of chitin and chitosan on blood coagulation. / Okamoto Y., Yano R., Miyatake K. Et al.// Carbohydr. Polym. 2003. — Vol. 53. — P. 337 342.
- Olivencia-Yurvati A.H. Intraoperative treatment strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation. / Olivencia-Yurvati A.H., Wallace W.E., Wallace N. et al. // Perfusion. 2002.- Vol. 17 (Suppl). — P. 35−39.
- Olson S.T. Demonstration of two-step reaction mechanism for inhibition of a-thrombin by antithrombin II and identification of the step affected by heparin. / Olson S.T., Shore J.D. // J. Biol. Chem. 1982. — Vol. 257. — P. 14 891−14 895.
- Ootaki Y. Effects of modified ultrafiltration on coagulation factors in pediatric cardiac surgery. / Ootaki Y., Yamaguchi M., Oshima Y. et al. // Surg. Today. 2002. — Vol. 32. — P. 203−206.
- Ootaki Y. The efficacy of preoperative administration of a single dose of recombinant human erythropoietin in pediatric cardiac surgery. / Ootaki Y., Yamaguchi M., Yoshimura N. et al. // Heart. Surg. Forum. 2007. Vol. 10. — P. El 15−119.
- O’Regan D.J. Topical aprotinin in cardiac operations. / O’Regan D.J., Giannopoulos N., Mediratta N. et al. // Ann. Thorac. Surg. 1994. — Vol. 58. P. 778−781.
- Oz M.C. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. / Oz M.C., Cosgrove D.M., Badduke B.R. et al. // Ann. Thorac. Surg. 2000. — Vol. 69. — P. 1376−1382.
- Ozer Z. The effect of aprotinin on ischemiareperfusion injury in the rabbit kidney. / Ozer Z., Sucu N., Dusmez D. et al. // Pharmacol. Res. 2001. — Vol. 44. -P. 455—460.
- Ozeren M. Consequences of PTFE membrane used for prevention of reentry injuries in rheumatic valve disease. / Ozeren M., Han U., Mavioglu I. et al. // Cardiovasc. Surg. 2002. — Vol. 10. — P. 489−493.
- Pagano D. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. / Pagano D., Howell N.J., Freemantle N. et al. // J. Thorac. Cardiovasc. Surg. 2008. — Vol. 135. — P. 495−502.
- Pandey R. Protective effects of aprotinin on respiratory and cardiac abnormalities induced by Mesobunthus tamulus venom in adult rats. / Pandey R., Deshpande S.B. // Toxicon. 2004. — Vol. 44. — P. 201−205.
- Park C.H. Three-dimencional structure of the kringle sequence: structure of prothrombin fragment 1. / Park C.H., Tulinsky A. // Biochemistry. 1986. — Vol. 25.-P. 3977−3982.
- Pedley T.J. The fluid mechanics of large blood vessels. / Pedley T.J. -Cambridge university press, 1980. (Педли Т. Гидродинамика крупных кровеносных сосудов. Пер. с англ. / Педли Т. М.: Мир, 1983. — 400 стр.)
- Pelletier М.Р. Negative reexploration for cardiac postoperative bleeding: can it be therapeutic? / Pelletier M.P., Solymoss S., Lee A. et al. // Ann. Thorac. Surg. 1998. — Vol. 65. — P. 999 -1002.
- Petaja J. Bleeding and use of blood products after heart operations in infants. / Petaja J., Lundstrom U., Leijala M. et al. // J. Thorac. Cardiovasc. Surg. 1995. -Vol. 109.-P. 524−529.
- Petaja J. Fibrinolysis, antithrombin III, and protein с in neonates during cardiac operations. / Petaja J., Peltola K., Sairanen H. et al. // J. Thorac. Cardiovasc. Surg. 1996. — Vol. 112. — P. 665−671.
- Petaja J. Cardiopulmonary bypass and activation of antithrombotic plasma protein C. / Petaja J., Pesonen E., Fernandez J.A. et al. // J. Thorac. Cardiovasc. Surg.- 1999.-Vol. 118.-P. 422−429.
- Peters M. Low antithrombin III levels in neonates with idiopathic respiratory distress syndrome: Poor prognosis. / Peters M., ten Cate J.W., Breederveld C. et al. // Pediatr. Res. 1984. — Vol. 18. — P. 273−276.
- Peters D.C. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. / Peters D.C., Noble S. // Drugs. 1999. — Vol. 57. — P. 233−260.
- Piffare R. (ed.) Management of bleeding in cardiovascular surgery. Hanley & Belfos Inc., Philadelphia, 2000. — 502 c.
- Pixley R.A. Effect of heparin on the activation of factor XII and the contact system in plasma. / Pixley R.A., Cassello A., De La Cadena R.A. et al. // Thromb. Haemost.- 1991.-Vol. 66.-P. 540−547.
- Pizarro C. Is there a role for extracorporeal life support after stage I Norwood? / Pizarro C., Davis D.A., Healy R.M. // Eur. J. Cardiothorac. Surg. -2001.-Vol. 19.-P. 294−301.
- Ploz F.B. Blood activation during neonatal extracorporeal life support. / Ploz F.B., Oeveren W., Bartlett R.H. et al. // J Thorac Cardiovasc Surg. 1993. — Vol. 105.-P. 823−832.
- Primack C. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. / Primack C., Walenga J. M, Koza M.J. et al. // Ann. Thorac. Surg. 1996. — Vol. 61. — P. 1188−1193.
- Pruefer D. Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reperfiision on the beating heart. / Pruefer D., Buerke U., Khalil M. et al. // J. Thorac. Cardiovasc. Surg. 2002. — Vol. 124. — P. 942 949.
- Pruefer D. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfiision. / Pruefer D., Makowski J., Dahm M. et al. // Ann. Thorac. Surg. 2003. — Vol. 75. — P. 210−215.
- Puckett R.M. Prophylactic vitamin K for vitamin K deficiency bleeding in neonates. / Puckett R.M., Offringa M. // Cochrane Database Syst. Rev. 2000. -CD002776.
- Rahe-Meyer N. Bleeding, management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. / Rahe-Meyer N., Pichlmaier M., Haverich A. et al. // British Journal of Anaesthesia. 2009. — Vol. 102. — P. 785−792.
- Rahman A. Does aprotinin reduce lung perfusion after cardiopulmonary bypass? / Rahman A., Ustunda B., Burma O. et al. // Eur. J. Cardiothorac. Surg. -2000,-Vol. 18.-P. 583−588.
- Ramlawi B. Serologic markers of brain injury and cognitive function after cardiopulmonary bypass. / Ramlawi B., Rudolph J.L., Mieno S. et al. // Ann. Surg. -2006.-Vol. 244.-P. 593−601.
- Ranby M. Enzymatic properties of the one- and two-chain forms of tissue plasminogen activator. / Ranby M, Bergsdorf N, Nilsson T. // Thromb. Res. -1982.-Vol. 27.-P. 175−183.
- Rao S.B. Use of chitosan as a biomaterial: studies, on its safety and hemostatic potential. / Rao S.B., Sharma C.P. // J. Biomed. Mater. Res. 1997. -Vol. 4.-P. 21−28.
- Razon Y. Recombinant factor Vila (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease. / Razon Y., Erez E., Vidne B. et al. // Paediatr. Anaesth. 2005. — Vol. 15. — P. 235−240.
- Reid R.W. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. / Reid R.W., Zimmerman A.A., Laussen P.C. et al. // Anesth. Analg. 1997. — Vol. 84. P. 990 996.
- Rijken D.C. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. / Rijken D.C., Groeneveld E. // J. Biol. Chem. 1986. — Vol. 261. — P. 3098−3102.
- Roach M.R. The reason for the shape of the distensibility curves arteries. / Roach M.R., Burton A.C. // Can. J. Biochem. Physiol. 1957. — Vol. 35. — P. 181 190.
- Roberts R.F. Addition of aprotinin to organ preservation solutions decreases lung reperfusion injury. / Roberts R.F., Nishanian G.P., Carey J.N. et al. // Ann. Thorac. Surg. 1998. — Vol. 66. — P. 225−230.
- Robicsek F. Microfibrillar collagen hemostat in cardiac surgery. / Robicsek F. // J. Thorac. Cardiovasc. Surg. 2004. — Vol. 127. — P. 1228.
- Rothschild J.M. Risks of complications by attending physicians after performing nighttime procedures. / Rothschild J.M., Keohane C.A., Rogers S. et al. //JAMA. 2009. — Vol. 302. — P. 1565−1572.
- Royston D. Effect of aprotinin on need for blood transfusion after repeat openheart surgery. / Royston D., Taylor K.M., Bidstrup B.P. et al. // Lancet. -1987. Vol. 330. — P. 1289−1291.
- Royston D. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen? / Royston D., Cardigan R., Gippner-Steppert C. et al. // Anesth. Analg. 2001. — Vol. 92. — P. 830−836.
- Royston D. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. / Royston D., Levy J.H., Fitch J. et al. // Anesth. Analg. 2006. — Vol. 103. — P. 1082−1088.
- Rubens F.D. Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer. / Rubens F.D., Labow R.S., Lavallee G.R. // Ann. Thorac. Surg. 1999. — Vol. 67. — P. 689−698.
- Rudolph A.M. Congenital disease of the heart. / Rudolph A.M. Chicago: Yearbook Medical Publishers, 1974.
- Ruggeri Z.M. The structure and function of von Willebrand factor. / Ruggeri Z.M., Ware J. // Thromb. Haemost. 1992. — Vol. 67. — P. 594−599.
- Ruggeri Z.M. Von Willebrand factor, platelets and endothelial cell interactions. / Ruggeri Z.M. // J. Thromb. Haemost. 2003. — Vol. 1. — P. 13 351 342.
- Salonvaara M. Effects of gestational age and prenatal and perinatal events on the coagulation status in premature infants. / Salonvaara M., Riikonen P., Kekomaki R. et al. // Arch. Dis. Child. Fetal. Neonatal. Ed. 2003. — Vol. 88. — P. F319-F323.
- Sanders J.M. The bleeding time may be longer in children than in adults. / Sanders J.M., Holtkamp C.A., Buchanan G.R. // Am. J. Pediatr. Hematol. Oncol. -1990. Vol. 12. — P. 314−318.
- Scher K.S. Effects of oxidized cellulose and microfibrillar collagen on infection. / Scher K.S., Coil J.A. Jr. // Surgery. 1982. — Vol. 91. — P. 301−304.
- Schini-Kerth V.B. Vascular biosynthesis of nitric oxide: effect of hemostasis and fibrinolysis. // Transfus. Clin. Biol. 1999. — Vol. 6. — P. 355−363.
- Schmaier A.H. Plasma kallikrein system: a revised hypothesis for its activation and its physiologic contributions. / Schmaier A.H. // Curr. Opin. Hematol. 2000. — Vol. 7. — P. 261−265.
- Schmidt B. Plasma From elimination of antithrombin III is accelerated in term newborn infants. / Schmidt B., Wais U., Pringsheim W., Kunzer W. // Eur. J. Pediatr. 1984. — Vol. 141. — P. 225−227.
- Schneeweiss S. Effect of aprotinin on renal dysfunction. / Schneeweiss S., Walker A.M., Seeger J.D. // Lancet. 2008. — Vol. 372. — P. 26−27.
- Schwarzenberg H. Hyperthermic fibrinolysis with rt-PA: in vivo study. / Schwarzenberg H., Muller-Hulsbeck S., Brossman J. et al. // Cardiovasc. Intervent. Radiol. 1998.-Vol. 21.-P. 142−145.
- Schweizer A. Aprotinin does not impair renal haemodynamics and function after cardiac surgery. / Schweizer A., Hohn L., Morel D.R. et al. // Br. J. Anaesth. -2000. Vol. 84.-P. 16−22.
- Sedrakyan A. Aprotinin use in thoracic aortic surgery: safety and outcomes. / Sedrakyan A., Wu A., Sedrakyan G. et al. // J. Thorac. Cardiovasc. Surg. 2006. -Vol. 132.-P. 909−917.
- Seear M.D. The effect of desmopression acetate (DDAVP) on postoperative blood loss after cardiac operations in children. / Seear M.D., Wadsworth L.D., Rogers P.C. et al. // J. Thorac. Cardiovasc. Surg. 1989. — Vol. 98. — P. 217−219.
- Seghaye C.M. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. / Seghaye C.M., Duchateau J., Grabitz GR. et al. // Ann. Thorac. Surg. 1996. — Vol. 61. — P. 1205−1211.
- Seto S. Central effect of aprotinin, a serine protease inhibitor, on blood pressure in spontaneously hypertensive and Wistar-Kyoto rats. / Seto S., Akahoshi M., Kusano S. et al. // Adv. Exp. Med. Biol. 1989. — Vol. 247. — P. 49−54.
- Shaw A.D. The effect of aprotinin on outcome after coronary-artery bypass grafting. Shaw A.D., Stafford-Smith M., White W.D. et al. // N. Engl. J. Med. -2008. Vol. 358. — P. 784−793.
- Shernan S.K. Perioperative myocardial ischemia reperfusion injury. // Anesthesiol. Clin. North. America. 2003. — Vol. 21. — P. 465−485.
- Shibata J. Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. / Shibata J., Hasegawa J., Siemens H.-J. et al. //Blood. 2003. — Vol. 101. — P. 4416−4422.
- Silveira F.M. Hemostatic changes in children treated with open heart surgery with cardiopulmonary bypass. / Silveira F.M., Lourenco D.M., Maluf M. et al. // Arquivos Brasileiros de Cardiologica. 1998. — Vol. 70. — P 29−35.
- Silver F.H. Viscoelasticity of the vessel wall: the role of collagen and elastic fibers. / Silver F.H., Horvath I., Foran D.J. // Crit. Rev. Biomed. Eng. 2001. -Vol. 29.-P. 279−301.
- Singh R. Aprotinin for open cardiac surgery in cyanotic heart disease. / Singh R., Vellaichamy M., Gowda N. et al. // Asian. Cardiovasc. Thorac. Ann. -2001.-Vol. 9. P. 101−104.
- Sirieix D. Does aprotinin modify the effects of ischaemia-reperfusion on the myocardial performance of a blood perfused isolated rabbit heart? / Sirieix D., Clinquart F., Delayance S. et al. // Eur. J. Anaesthesiol. 1999. — Vol. 16. — P. 712−718.
- Smyth S.S. Regulation of vascular integrins. / Smyth S.S., Joneckis C.C., Parise L.V. // Blood. 1993. — Vol. 81. — P. 2827−2843.
- Soslau G. The effect of tranexamic acid onplatelet ADP during extracorporeal circulation. / Soslau G., Horrow J., Brodsky I. // Am. J. Hematol. -1991.-Vol. 38.-P. 113−119.
- Spangler D. In vitro antimicrobial activity of oxidized regenerated cellulose against antibiotic-resistant microorganisms. / Spangler D., Rothenburger S., Nguyen K. et al. // Surg. Infect. 2003. — Vol. 4. — P. 255−262.
- Speekenbrink R.G. Low dose and high-dose aprotinin improve hemostasis in coronary operations. / Speekenbrink R.G., Wildevuur C.R., Sturk A. et al. // J. Thorac. Cardiovasc. Surg. 1996. — Vol. 112. — P. 523−530.
- Spiess B.D. Transfusion of blood products affects outcome in cardiac surgery. / Spiess B.D. // Semin. Cardiothorac. Vase. Anesth. 2004. — Vol. 8. — P. 267−281.
- Stark J. Reoperations in cardiac surgery. // Stark J., Pacifico A.D. -Springer-Verlag, New York, Heidelberg, 1989. p. 161 — 185.
- Stuklis R.G. Novel approach to bleeding in patients undergoing cardiac surgery with liver dysfunction. / Stuklis R.G., O’Shaughnessy D.F., Ohri S.K. // Eur. J. Cardiothorac. Surg. 2001. — Vol. 19. — P. 219−220.
- Sugita T. Repeated procedure after radical surgery for tetralogy of Fallot. / Sugita T., Ueda Y., Matsumoto M., et al. // Ann. Thorac. Surg. 2000. — Vol. 70. -P. 1507−1510.
- Sugiyama N. Binding site of a2-plasmin inhibitor to plasminogen. / Sugiyama N., Sasaki T., Iwamoto M. et al. // Biochim. Biophys. Acta. 1988. -Vol. 952.-P. 1−7.
- Suttie J.W. Studies of the vitamin K-dependent carboxylase and vitamin K epoxide reductase in rat liver. / Suttie J.W., Preusch P.C. // Haemostasis. 1986. -Vol. 16.-P. 193−215.
- Suzuki Y. Platelet anesthesia with nitric oxide with and without eptifibatide during cardiopulmonary bypass in baboons. / Suzuki Y., Malekan R., Hansen C.W. et al. // J. Thorac. Cardiovasc. Surg. 1999. Vol. 117. — P. 987−993.
- Szekely A. Risks and predictors of blood transfusion in pediatric patients undergoing open heart operations. / Szekely A., Cserep Z., Sapi E. et al. // Ann. Thorac. Surg. 2009. — Vol. 87. — P. 187−197.
- Taby O. Inhibition of activated protein C by aprotinin and the use of the insolublized inhibitor for its purification. / Taby O., Chabbat J., Steinbuch M. // Thromb. Res. 1990. — Vol. 59. — P. 27−35.
- Takada A. Physiology of plasminogen: with special reference to activation and degradation. Takada A., Takada Y. // Haemostasis. 1988. — Vol. 18 (Suppl. 1).-P. 25−35.
- Takahashi H. Role of tissue plasminogen activator/plasmin cascade in delayed neuronal death after transient forebrain ischemia. / Takahashi H., Nagai N., Urano T. //Neurosci. Lett. -2005. Vol. 381. — P. 189−193.
- Tatar H. Topical use of aprotinin in open heart operations. / Tatar H., Cicek S., Demirkilic U. et al. // Ann. Thorac. Surg. 1993. — Vol. 55. — P. 659−661.
- Teger-Nilsson A.C. Fibrinogen to fibrin transformation in umbilical cord blood and purified neonatal fibrinogen. / Teger-Nilsson A.C., Ekelund H. // Thromb. Res. 1974. — Vol. 5. — P. 601−612.
- Tesch R. Electron microscopic studies on the foetal fibrin clot. / Tesch R., Trolp R., Witt I. // Thromb. Res. 1979. — Vol. 16. — P. 239−243.
- Teufelsbauer H. Early activation of haemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. / Teufelsbauer H., Proidl S., Havel M., Vukovich T. // Thromb. Haemost.- 1992. -Vol. 68. P. 250 252.
- Thies W.-R. Fibrinogen half-life in children with cyanotic congenital heart disease. / Thies W.-R., Gobel U., Liersch R. // Eur. J. Pediatr. 1982. — Vol. 139. -P. 43−47.
- Tobias J. Recombinant factor Vila to control excessive bleeding following surgery for congenital heart disease in pediatric patients. / Tobias J., Sinsic J., Weinstein S. et al. // J. Intensive Care Med. 2004. — Vol. 19. — P. 270−273.
- Tredree R.B.W. Evaluating the difference between fibrin sealants: recommendations from an international advisory panel of hospital pharmacists. / Tredree R.B.W., Debrix I., Eisert A. et al. // EJHP Science. 2006. — Vol. 12. — P. 3−9.
- Tselentakis E.V. Inflammation effects on the electrical properties of atrial tissue and inducibility of postoperative atrial fibrillation. / Tselentakis E.V., Woodford E., Chandy J. et al. // J. Surg. Res. 2006. — Vol.135. — P. 68−75.
- Ulker S. Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells. / Ulker S., Cinar M.G., Bayraktutan U. et al. // Cardiovasc. Res. 2001. — Vol. 50. — P. 589 596.
- Ulker S. Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. / Ulker S., McKeown P.P., Bayraktutan U. // Cardiovasc. Res. 2002. — Vol. 55. — P. 830 837.
- Vadhan-Raj S. Clinical experience with recombinant human thrombopoeitin in chemotherapy-induced thrombocytopenia. / Vadhan-Raj S. / Semin. Hematol. -2000, — Vol. 37. P. 28−34.
- Valen G. Fibrinolysis during cardiac surgery. / Valen G., Eriksson E., Risberg B., Vaage J. // Eur. J. Cardiothorac. Surg. 1994. — Vol. 8. — P. 324−330.
- Valeri C.R. Hypothermia-induced reversible platelet dysfunction. / Valeri C.R., Cassidy G., Khuri S. et al. // Ann. Surg. 1986. Vol. 205. — P. 175−181.
- Vandendries E.R. PAR-4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. / Vandendries E.R., Hamilton J.R., Coughlin S.R. et al. // Proc. Natl. Acad. Sci. USA. 2007. -Vol. 104.-P. 288−292.
- Varela Crespo C.A. Effect of tranexamic acid on postoperative bleeding in pediatric heart surgery. / Varela Crespo C.A., Sanabria Carretero P., Palomero Rodriguez M. A et al. // Rev. Esp. Anestesiol. Reanim. 2007. — Vol. 54. — P. 155 161.
- Varga-Szabo D. Cell adhesion mechanisms in platelets. / Varga-Szabo D., Pleines I., Nieswandt B. // Arterioscler. Thromb. Vase. Biol. 2008-. — Vol. 28. — P. 403 -412.
- Venturini G. Aprotinin, the first competitive protein inhibitor of NOS activity. / Venturini G., Colasanti M., Ascenzi P. // Biochem. Biophys. Res. Commun. 1998. — Vol. 249. — P. 263−265.
- Verstraete M. Clinical application of inhibitors of fibrinolysis. // Drugs. -1985. Vol. 29. — P. 236−261.
- Wachtfogel Y.T. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. / Wachtfogel Y.T., Kucich U., Hack C.E. et al. // J. Thorac. Cardiovasc. Surg. 1993. — Vol. 106. — P. 1−9.
- Wagener G. Aprotinin increases urinary NGAL, a marker for renal tubular injury after cardiac surgery. / Wagener G., Gubitosa G., Jalbout M. et al. // Anesthesiology. 2006. — Vol. 105. — A1732.
- Wagner D.D. Cell biology of von Willebrand factor. / Wagner D.D. // Ann. Rev. Cell. Biol. 1990. — Vol. 6. — P. 217−246.
- Wang G. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. / Wang G., Bainbridge D., Martin J., Cheng D. // Anesth Analg. 2009. — Vol. 109. P. 320−330.
- Watkins M.N. Coagulation changes in the newborn with respiratory failure. / Watkins M.N., Swan S., Caprini J.A. et al. // Thromb. Res. 1980. — Vol. 17. — P. 153−175.
- Waxier B. Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ace inhibitors. / Waxier B., Rabito S. // Curr. Pharm. Design. -2003.-Vol. 9.-P. 777−787.
- Wedemeyer A.L. Improvement in hemostasis following phlebotomy in cyanotic patients with heart disease. / Wedemeyer A.L., Lewis J.H. // J. Pediatr. -1973.-Vol. 83.-P. 46−50.
- Wegner J. Biochemistry of serine protease inhibitors and their mechanisms of action: a review. // J. Extra. Corpor. Technol. 2003. — Vol. 35. — P. 326−338.
- Whitten C.W. D-dimer formation during cardiac and noncardiac thoracic surgery. / Whitten C.W., Greilich P.E., Ivy R. et al. // Anesth. Analg. 1999. -Vol. 88. — P. 1226−1231.
- Williams G.D. Association between age and blood loss in children undergoing open heart operations. / Williams G.D., Bratton S.L., Riley E.C., Ramamoorthy C. // Ann. Thorac. Surg. 1998. — Vol. 66. — P. 870−876.
- Williams G.D. Efficacy of epsilon-aminocaproic acid in children undergoing cardiac surgery. / Williams G.D., Bratton S.L., Riley E.C., Ramamoorthy C. // J. Cardiothorac. Vase. Anesth. 1999. — Vol. 13. — P. 304−308.
- Williams G.D. Factors associated with blood loss and blood product transfusions: amultivariate analysis in children after open-heart surgery. / Williams G.D., Bratton S.L., Ramamoorthy C. // Anesth. Analg. 1999. — Vol. 89. — P. 5764.
- Wilson A. Bone-marrow haematopoetic-stem-cell niches. / Wilson A., Trumpp A. // Nat. Rev. Immunol. 2006. — Vol. 6. — P. 93−106.
- Wippermann C.F. Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. / Wippermann C.F., Schmid F.X., Eberle B. et al. // Ann. Thorac. Surg. 1999. — Vol. 67. — P. 173−176.
- Witt I. Evidence for the existence of foetal fibrinogen. / Witt I., Muller H., Kunzer W. // Thromb. Diath. Haemorrh. 1969. — Vol. 22. — P. 101−109.
- Woodman R.C. Bleeding complications associated with cardiopulmonary bypass. / Woodman R.C., Harker L.A. // Blood. 1990. — Vol. 76. — P. 1680−1697.
- Wound closure manual. / Ethicon, Johnson and Johnson Co., 1994. 143 p.
- Wright D. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. / Wright D., Bowman E., Wagers A. et al. // J. Exp. Med. 2002. — Vol. 195. — P. 1145−1154.
- Yang Z. Effect of tissue plasminogen activator on vascular smooth muscle cells. / Yang Z., Eton D., Zheng F. et al. // J. Vase. Surg. 2005. — Vol. 42. — P. 532−538.
- Yun T.J. Aprotinin attenuates the elevation of pulmonary vascular resistance after cardiopulmonary bypass. / Yun T.J., Rho J.R. // J. Korean. Med. Sci. 2006. -Vol. 21.-P. 25−29.
- Zhang X. Effects of aprotinin on extravascular lung water in patients undergoing mitral valve replacement. / Zhang X., Liu B. // Anesthesiology. 2006. -Vol. 105.-A1227.